Most cited papers from Swim Across America

Swim Across America

What are the most cited papers from Swim Across America?

The most cited paper from Swim Across America is "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency" (Dung Thi Le et al., 2015), with 9,595 citations. Next come "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade" (6,813) and "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies" (5,211).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 150 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Dung Thi Le et al. · New England Journal of Medicine Open access	30 May 2015	9,595
2	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Dung Thi Le et al. · Science Open access	27 Jul 2017	6,813
3	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies Chetan Bettegowda et al. · Science Translational Medicine Open access	19 Feb 2014	5,211
4	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Alexandra Snyder et al. · New England Journal of Medicine Open access	20 Nov 2014	4,426
5	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer Patrick M. Forde et al. · New England Journal of Medicine Open access	16 Apr 2018	2,183
6	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Luis Alberto Diaz, Richard Thomas Williams, Jian Wu et al. · Nature Open access	Jun 2012	1,760
7	DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors Yuchen Jiao, Chanjuan Shi, Barish H. Edil et al. · Science Open access	20 Jan 2011	1,727
8	Cancer/testis antigens, gametogenesis and cancer Andrew J.G. Simpson, Otávia L. Caballero, Achim A. Jungbluth et al. · Nature reviews. Cancer Review	20 Jul 2005	1,613
9	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer Australian Pancreatic Cancer Genome Initiative et al. · Nature Open access	Nov 2017	1,242
10	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Lorenzo Galluzzi et al. · Journal for ImmunoTherapy of Cancer Open access	Mar 2020	1,116
11	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures Yasin Şenbabaoğlu et al. · Genome biology Open access	17 Nov 2016	1,056
12	Clinical implications of T cell exhaustion for cancer immunotherapy Andrew T. Chow, Karlo Perica, Christopher Austin Klebanoff et al. · Nature Reviews Clinical Oncology ReviewOpen access	10 Oct 2022	1,043
13	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways Lukas Kraehenbuehl, Chien‐Huan Weng, Shabnam Z Eghbali et al. · Nature Reviews Clinical Oncology Review	27 Sep 2021	903
14	Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells Olivier De Henau et al. · Nature Open access	Nov 2016	893
15	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors Shihao Xu et al. · Immunity Open access	7 Jun 2021	815
16	The head and neck cancer immune landscape and its immunotherapeutic implications Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard et al. · JCI Insight Open access	19 Oct 2016	804
17	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy Dmitriy Zamarin, Rikke Holmgaard, Sumit Kumar Subudhi et al. · Science Translational Medicine Open access	5 Mar 2014	712
18	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Marta Łuksza, Nadeem Riaz, Vladimir Makarov et al. · Nature Open access	Nov 2017	685
19	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors Haiping Wang, Fabien Franco, Yao-Chen Tsui et al. · Nature Immunology Open access	17 Feb 2020	681
20	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 Rikke Holmgaard, Dmitriy Zamarin, David H. Munn et al. · The Journal of Experimental Medicine Open access	10 Jun 2013	641
21	Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas Yuchen Jiao et al. · Oncotarget Open access	31 Jul 2012	590
22	Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response Rajarsi Mandal et al. · Science Open access	2 May 2019	587
23	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Justina X. Caushi et al. · Nature Open access	21 Jul 2021	574
24	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer Dung Thi Le, Eric R. Lutz, Jennifer N. Uram et al. · Journal of Immunotherapy Open access	6 Aug 2013	564
25	Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells Mary Jo Turk, Jose Alejandro Guevara-Patino, Gabrielle A. Rizzuto et al. · The Journal of Experimental Medicine Open access	20 Sep 2004	541
26	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · Cancer Cell Open access	Apr 2018	534
27	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine Luís Felipe Campesato, Sadna Budhu, Jeremy H. Tchaicha et al. · Nature Communications Open access	11 Aug 2020	517
28	The genomic landscape of response to EGFR blockade in colorectal cancer Andrea Bertotti et al. · Nature Open access	29 Sep 2015	500
29	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner Rikke Holmgaard, Dmitriy Zamarin, Yanyun Li et al. · Cell Reports Open access	24 Sep 2015	499
30	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient Alejandro Jiménez-Sánchez, Danish Memon, Stephane Pourpe et al. · Cell Open access	Aug 2017	474
31	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours Roberta Zappasodi et al. · Nature Open access	15 Feb 2021	404
32	Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses Nicholas Jason Roberts et al. · Science Translational Medicine Open access	13 Aug 2014	401
33	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition Barzin Y. Nabet et al. · Cell Open access	Oct 2020	373
34	Neutrophil phenotypes and functions in cancer: A consensus statement Daniela F. Quail et al. · The Journal of Experimental Medicine Open access	6 May 2022	364
35	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity John Alec Moral et al. · Nature Open access	19 Feb 2020	353
36	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers Isaac Kinde, Chetan Bettegowda, Yuxuan Wang et al. · Science Translational Medicine Open access	9 Jan 2013	327
37	T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants Daniel Hirschhorn et al. · Cell Open access	Mar 2023	312
38	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis Jun Li et al. · Cancer Discovery Open access	28 Dec 2020	301
39	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity Sydney X. Lu et al. · Cell Open access	24 Jun 2021	297
40	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade Valerie Lee, Adrian Gerard Murphy, Dung Thi Le et al. · The Oncologist Open access	13 Jul 2016	284
41	Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells Dianna Wu, Neil Howard Segal, Stéphane Sidobre et al. · The Journal of Experimental Medicine Open access	7 Jul 2003	280
42	TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine Isaac Kinde, Enrico Munari, Sheila F. Faraj et al. · Cancer Research Open access	12 Oct 2013	255
43	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade Tavi Nathanson, Arun Kumar Ahuja, Alex Rubinsteyn et al. · Cancer Immunology Research Open access	12 Dec 2016	246
44	Rational design of anti-GITR-based combination immunotherapy Roberta Zappasodi, Cynthia A. Sirard, Yanyun Li et al. · Nature Medicine Open access	29 Apr 2019	233
45	Tumor immunity and autoimmunity induced by immunization with homologous DNA. Lawrence W. Weber, Wilbur Bo Bowne, Jedd D. Wolchok et al. · Journal of Clinical Investigation Open access	15 Sep 1998	230
46	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics Neil Howard Segal, Paul Pavlidis, Cristina R. Antonescu et al. · American Journal Of Pathology Open access	Aug 2003	224
47	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade Evan J. Lipson, Victor E. Velculescu, Theresa S. Pritchard et al. · Journal for ImmunoTherapy of Cancer Open access	Dec 2014	218
48	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer Marta Łuksza et al. · Nature Open access	19 May 2022	211
49	Heteroclitic Immunization Induces Tumor Immunity Ruben Dyall, Wilbur Bo Bowne, Lawrence W. Weber et al. · The Journal of Experimental Medicine Open access	2 Nov 1998	205
50	Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Danish Memon et al. · Cancer Cell Open access	11 Jan 2024	203

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.